{"id":"W4313252429","doi":"10.1016/j.jtct.2022.12.017","title":"Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Sanofi Genzyme; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; HistoGenetics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Mallinckrodt Pharmaceuticals; Astellas Pharma US; CSL Behring; Eli Lilly and Company; Bristol-Myers Squibb; Amgen; Medac; Jazz Pharmaceuticals; Be The Match Foundation","keywords":"Medicine; Cyclophosphamide; Internal medicine; Transplantation; Incidence (geometry); Bone marrow; Clinical trial; Prospective cohort study; Clinical endpoint; Surgery; Hematopoietic stem cell transplantation; Hematopoietic cell; Gastroenterology; Oncology; Chemotherapy; Haematopoiesis; Stem cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002169065,0.0005996073,0.001371181,0.0004072851,0.0005996196,0.001406093,0.0005225377,0.0009580933,0.0009600783],"category_scores_gemma":[0.001714751,0.0002565772,0.001724438,0.000804261,0.0006189637,0.0009264563,0.000538288,0.001357739,0.0002347053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006919842,"about_ca_system_score_gemma":0.0007171206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001461846,"about_ca_topic_score_gemma":0.001707785,"domain_scores_codex":[0.9991067,0.0003680123,0.00007937278,0.0001304461,0.0001096036,0.0002058669],"domain_scores_gemma":[0.9983823,0.0003352551,0.0005810899,0.0001647533,0.0001141603,0.0004224871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4104061,0.007783972,0.5471298,0.0002580543,0.004340944,0.0006129511,0.0002323097,0.001124906,0.004954444,0.0002080293,0.0009217664,0.02202656],"study_design_scores_gemma":[0.03215977,0.07365224,0.8844189,0.00006851996,0.004221988,0.0006362334,0.0003739126,0.001115125,0.001691297,0.0002958455,0.001284276,0.0000818873],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985713,0.0007550697,0.00005373444,0.00004047594,0.00001702982,0.00003970344,0.0002345829,0.000002334654,0.0002857536],"genre_scores_gemma":[0.9985256,0.0002921891,0.00003869837,0.00009019738,0.00003249698,0.00004170078,0.0007477307,0.0000017815,0.0002296704],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002169065,"threshold_uncertainty_score":0.01147121,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04516008171446839,"score_gpt":0.3226275748341489,"score_spread":0.2774674931196805,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}